SCHLIEREN, Switzerland & OSAKA, Japan--(BUSINESS WIRE)--Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (“Ono”). Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets.

“We look forward to collaborating with Memo Therapeutics AG’s team of antibody scientists through this collaboration and hope that the candidates generated through our collaboration will add to our current portfolio of medicines to help cancer patients in immuno-oncology”

Tweet this

Ono will acquire intellectual property rights and worldwide exclusive rights to develop and commercialize therapeutic drug candidates with antibodies resulting from the collaboration. MTx will receive an upfront payment, research funding during the collaboration period, clinical development and sales milestones, as well as royalties on future sales.

“Ono with their proven track-record in the immune-oncology space is an ideal partner to advance this program. We are delighted to take this important step as the partnership recognizes our platform’s ability to identify high-value targets and create functionally superior antibodies in the immuno-oncology field,” said Dr. Christoph Esslinger, Chief Scientific Officer and founder of Memo Therapeutics AG.

“We look forward to collaborating with Memo Therapeutics AG’s team of antibody scientists through this collaboration and hope that the candidates generated through our collaboration will add to our current portfolio of medicines to help cancer patients in immuno-oncology,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical.

About Memo Therapeutics AG

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple, and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency, and sensitivity.

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects. The company’s current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Schlieren/Zurich, Switzerland.

Contacts

Memo Therapeutics AG
Karsten Fischer
media@memo-therapeutics.com

Halsin Partners
Mike Sinclair
+44 (0) 7968 022075
msinclair@halsin.com